GH · Guardant Health, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on GH. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About GH · Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Live Quote
HOLD (score +4) · 12-1 mom 136.1% · RSI 62.4 · above_both · -1.8% from high
Targets blend Wall Street consensus (23 analysts: low $90.00 / mean $143.09 / high $190.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
Lessons Referencing This Ticker
For zero-revenue resource companies, earnings reports are operational milestone updates, not financial performance events. Market reaction is typically delayed 3-7 days as analysts digest operational details (mine start-up, production targets, inventory decisions). Use longer-dated options (7-14 DTE) or calendar spreads instead of tight DTE spreads that expire before the full reaction.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
In low-float, high-short-interest commodity names (~10%+ shorts), pre-earnings positioning can cause large directional spikes (10-15%) that distort entry pricing and skew readings. These spikes are driven by gamma positioning and short-covering, not fundamental information. Enter spreads AFTER the pre-event spike resolves, not before.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
When directional thesis is correct but the move occurs after option expiry, the trade is a technical win but a strategic loss. The capital is locked up during the delayed reaction period, and theta decay continues. For binary operational events, consider selling the put spread leg to finance a longer-dated call/put if the directional conviction is high but timing is uncertain.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
For pre-revenue mining companies, the key earnings catalyst is operational progress (mine start-up, production targets, permitting status), not EPS. EPS misses are expected and priced in. Market reaction is driven by whether operational milestones are met or delayed, not financial performance. Score catalysts based on operational milestone significance, not EPS surprise potential.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
When RSI(14) > 80 AND the stock has run up >40% in 180 days entering earnings, the probability of mean-reversion is high regardless of implied move richness. The direction_evidence score should be reduced by at least 5 points, and the trade should be avoided unless there is a strong contrarian catalyst.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call
In cybersecurity names during AI-capex peaks, executive sales (even Rule 10b5-1) at prices significantly below current spot should be weighted more heavily than analyst upgrades. Insiders are closer to the data and may be positioning for a plateau.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call
Historical EPS beats do not guarantee positive stock reaction if the stock has already run up into the event. The 'beat' is priced in, and any 'in-line' result is a disappointment. The catalyst_was_real score should be reduced when the pre-event run-up exceeds 20%.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call
RSI(14) > 80 is a valid overbought signal that should reduce the technical_was_useful score and trigger a mean-reversion warning. In the scoring methodology, technical signals should not be dismissed as 'Tier 3 confirmation' when they indicate extreme conditions.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call